FDA Approves New Use for Invega Sustenna
Janssen Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Applications (sNDAs) for the once-monthly atypical long-acting antipsychotic INVEGA® SUSTENNA® (paliperidone palmitate) to treat schizoaffective disorder as either monotherapy or adjunctive therapy.
Injectable Schizophrenia Medications: The Old vs the New
Schizophrenia can be treated with oral or injectable medications. The injections last longer and may help to keep patients from stopping treatment. But it's still unclear if newer injectable medications work better than the older ones.